In this thesis, we describe the development, identification and characterization of four novel anti-complement nanobodies. This shows that the development of nanobodies against complement proteins is a good approach to develop these kinds of new molecules and tools. The nanobodies described in this thesis can be used now and in the future to further unravel important fundamental and clinical issues related to the complement system. In addition, some of these nanobodies could be used to develop new drugs that can inhibit overactivity of the complement system.
